Table S1.
Patient | Type of HL | Radiation | Transplant | Number of prior therapies | Age, y | Sex | Karnofsky score | Serum-soluble IL-2 receptor | Malignant cells positive for CD25 | CD25 expression by rosetting T cells |
1 | Classic | No | No | 4 | 34 | Male | 70 | 3,418 | Negative | Positive |
2 | Classic | Yes | No | 7 | 38 | Male | 90 | 644 | <10% | Positive |
3 | Classic | No | Allo/auto | 7 | 34 | Male | 90 | 3,454 | <10% | Positive |
4 | Classic | Yes | No | 4 | 58 | Female | 90 | <600 | >50% | Positive |
5 | Classic | Yes | Auto | 3 | 40 | Female | 90 | <1,200 | <10% | Positive |
6 | Classic | Yes | No | 2 | 24 | Male | 90 | 1,710 | Negative | Positive |
7 | Classic | Yes | Auto | 5 | 43 | Male | 90 | <1,200 | >50% | Positive |
8 | Classic | Yes | Auto | 3 | 24 | Male | 90 | 625 | Negative | Positive |
9 | Classic | Yes | Allo/auto | 8 | 41 | Female | 90 | <1,250 | Negative | Positive |
10 | Classic | Yes | No | 1 | 36 | Male | 90 | <620 | <10% | Positive |
11 | Classic | Yes | Allo/auto | 4 | 34 | Female | 80 | <1,230 | <10% | Positive |
12 | Classic | Yes | Auto | 3 | 64 | Male | 90 | <1,250 | >90% | Positive |
13 | Classic | Yes | Auto | 7 | 38 | Male | 90 | 700 | <10% | Positive |
14 | Classic | Yes | Auto | 5 | 24 | Male | 80 | <1,270 | Negative | Positive |
15 | Classic | Yes | No | 5 | 66 | Male | 80 | 4,460 | <10% | Positive |
16 | Classic | Yes | Allo/auto | 7 | 35 | Male | 90 | Not done | >25% | Positive |
17 | Classic | Yes | Auto | 6 | 27 | Male | 100 | <1,140 | Negative | Positive |
18 | Classic | Yes | Auto | 4 | 32 | Male | 90 | <1,135 | Negative | Positive |
19 | Classic | No | Auto | 3 | 22 | Male | 80 | 4,000 | Negative | Positive |
20 | Classic | No | Auto | 6 | 36 | Female | 90 | 1,550 | Negative | Positive |
21 | Classic | Yes | Auto | 3 | 41 | Male | 90 | <1,145 | >25% | Positive |
22 | Classic | No | Auto | 6 | 49 | Male | 90 | <1,135 | Negative | Positive |
23 | Classic | Yes | No | 5 | 32 | Female | 70 | 11,900 | <10% | Positive |
24 | Classic | Yes | Auto | 6 | 22 | Female | 90 | 755 | <10% | Positive |
25 | Classic | No | Auto | 4 | 67 | Male | 100 | 700 | Negative | Positive |
26 | Classic | Yes | No | 5 | 23 | Male | 100 | 580 | Negative | Positive |
27 | Classic | Yes | Auto | 3 | 31 | Female | 90 | <1,125 | Negative | Positive |
28 | Classic | Yes | Auto | 4 | 20 | Female | 90 | 2,200 | Negative | Positive |
29 | Classic | No | Auto | 6 | 31 | Female | 80 | 2,532 | Negative | Positive |
30 | Classic | Yes | Allo/auto | 21 | 28 | Male | 80 | 2,380 | Negative | Positive |
31 | Classic | Yes | No | 3 | 42 | Female | 80 | 2,946 | Positive | Positive |
32 | Classic | Yes | No | 5 | 77 | Female | 90 | 5,813 | Negative | Positive |
33 | Classic | No | Auto | 13 | 29 | Male | 2,744 | Positive | Positive | |
34 | Classic | Yes | Auto | 11 | 29 | Female | 90 | 4,504 | Negative | Positive |
35 | Classic | Yes | Auto | 8 | 36 | Female | 80 | 16,714 | Positive | Not done |
36 | Classic | Yes | No | 3 | 32 | Female | 100 | 348 | Weak focal | Positive |
37 | Classic | No | Auto | 7 | 29 | Male | 70 | 7,504 | Positive | Positive |
38 | Classic | Yes | Auto/allo | 17 | 30 | Male | 70 | 9,220 | Not done | Not done |
39 | Classic | Yes | Auto | 4 | 24 | Male | 100 | 511 | Negative | Positive |
40 | Classic | No | Auto | 5 | 41 | Male | 70 | 2,715 | Positive | Positive |
41 | NLP | Yes | No | 2 | 30 | Male | 90 | 1,250 | Negative | Positive |
42 | NLP | No | No | 2 | 36 | Male | 100 | <1,140 | Negative | Positive |
43 | NLP | No | Allo/auto | 16 | 38 | Male | 80 | 8,046 | Negative | Positive |
44 | NLP | Yes | Auto | 8 | 47 | Female | 90 | 2,487 | Negative | Positive |
45 | NLP | Yes | No | 7 | 27 | Female | 90 | 8,899 | Negative | Positive |
46 | NLP | No | Auto | 11 | 41 | Male | 70 | 7,452 | Positive for rare RS cells | Not done |
Allo, allogeneic transplant; Auto, autologous transplant; RS, Reed–Sternberg.